Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole

被引：26

作者：

Avery, Lisa M. ^{[2
,3
]}

Steed, Molly E. ^{[1
]}

Woodruff, Ashley E. ^{[2
]}

Hasan, Muhammad ^{[3
]}

Rybak, Michael J. ^{[1
,4
]}

机构：

[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48202 USA

[2] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA

[3] St Josephs Hosp, Ctr Hlth, Syracuse, NY USA

[4] Wayne State Univ, Sch Med, Detroit, MI USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 11期

关键词：

VITRO PHARMACOKINETIC/PHARMACODYNAMIC MODEL; INFECTIONS; SUSCEPTIBILITY; OUTCOMES; THERAPY; SAFETY;

D O I：

10.1128/AAC.01046-12

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus ( VISA) vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxazole should be explored further for the treatment of DNS VISA strains.

引用

页码：5990 / 5993

页数：4

共 26 条

[1] Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole [J].

Alappan, R ;

Perazella, MA ;

Buller, GK .

ANNALS OF INTERNAL MEDICINE, 1996, 124 (03) :316-320

[2] Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].

Benvenuto, Mark ;

Benziger, David P. ;

Yankelev, Sara ;

Vigliani, Gloria .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249

[3] EFFECT OF TRIMETHOPRIM-SULFAMETHOXAZOLE ON RENAL EXCRETION OF CREATININE IN MAN [J].

BERGLUND, F ;

KILLANDER, J ;

POMPEIUS, R .

JOURNAL OF UROLOGY, 1975, 114 (06) :802-808

[4] Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis [J].

Bhavnani, Sujata M. ;

Rubino, Christopher M. ;

Ambrose, Paul G. ;

Drusano, George L. .

CLINICAL INFECTIOUS DISEASES, 2010, 50 (12) :1568-1574

[5]

Burdette Steven D, 2009, Spine J, V9, pe5, DOI 10.1016/j.spinee.2008.11.008

[6]

Clinical and Laboratory Standards Institute, 2011, M7A9 CLIN LAB STAND

[7] Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus [J].

Close, SJ ;

McBurney, CR ;

Garvin, CG ;

Chen, DC ;

Martin, SJ .

PHARMACOTHERAPY, 2002, 22 (08) :983-989

[8]

Cubist Pharmaceuticals Inc, 2003, CUB PACK INS

[9] Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence [J].

Falagas, Matthew E. ;

Giannopoulou, Konstantina P. ;

Ntziora, Fotinie ;

Papagelopoulos, Panayiotis J. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (03) :202-209

[10] Safety of High-Dose Intravenous Daptomycin Treatment: Three-Year Cumulative Experience in a Clinical Program [J].

Figueroa, D. A. ;

Mangini, E. ;

Amodio-Groton, M. ;

Vardianos, B. ;

Melchert, A. ;

Fana, C. ;

Wehbeh, W. ;

Urban, C. M. ;

Segal-Maurer, S. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (02) :177-180

← 1 2 3 →